Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial
Nanocurcumin-Supplementierung verbessert die Lungenfunktion bei Patient:innen mit schwerer COPD: randomisierte, doppelblinde, placebokontrollierte klinische Studie
Phytotherapy Research · 2024-03 · 38 (3) · 1224-1234
DOI: 10.1002/ptr.8114 ↗Auf einen Blick
Bei 60 Patient:innen mit COPD Stadium 3 und 4 verbesserte Nanocurcumin über 3 Monate Entzündungs- und Atemparameter gegenüber Placebo. IL-6 sank, FEV1, FVC und FEV1/FVC stiegen.
Fragestellung
Wirkt 80 mg Nanocurcumin über 3 Monate auf Atemparameter und IL-6 bei Patient:innen mit schwerer COPD?
Methode
Doppelblinde, placebokontrollierte randomisierte klinische Studie mit 60 Patient:innen; 80 mg Nanocurcumin oder Placebo für 3 Monate.
Ergebnisse
IL-6 nahm unter Nanocurcumin signifikant ab (p < 0,001). FEV1 (p < 0,001), FVC (p = 0,003) und FEV1/FVC (p < 0,001) stiegen gegenüber Placebo. Gewicht, BMI und systolischer Blutdruck verbesserten sich ebenfalls.
Schlussfolgerung der Autor:innen
Nanocurcumin scheint günstige Effekte auf den Entzündungsstatus und respiratorische Indizes bei Patient:innen mit schwerer COPD zu haben.
Kernaussagen
- IL-6 sank unter Nanocurcumin signifikant
- FEV1, FVC und FEV1/FVC stiegen gegenüber Placebo
- Auch Gewicht, BMI und systolischer Blutdruck verbesserten sich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Randomisierte kontrollierte Studie in Phytotherapy Research, published online on 2024-01-04. Written by Mahdieh Zare'i and 4 co-authors. Institution: Department of Nutrition, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. Major MEDLINE topics: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Curcumin. Cited 22 times so far (Crossref); 64 references. Funded by: Urmia University of Medical Sciences.
Topics: COPD
Abstract (original language)
Considering the anti‐inflammatory properties of curcumin, the present study was designed to investigate the effect of nano‐curcumin on respiratory indices and interleukin‐6 (IL‐6) levels in severe chronic obstructive pulmonary disease (COPD) patients as a common pulmonary disease causing restricted airflow and breathing problems. In the current double‐blind placebo‐controlled randomized clinical trial study, 60 patients with stages 3 and 4 COPD were randomly assigned into 80 mg nano‐curcumin ( n = 30) and placebo groups ( n = 30) for 3 months. The effect of nano‐curcumin on pulmonary function was evaluated by the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC) ratio. IL‐6 serum level, blood pressure, and anthropometric indices were also measured. Nano‐curcumin supplementation led to a significant decrease in IL‐6 level ( p < 0.001) and an increase in FEV1 ( p < 0.001), FVC ( p = 0.003), and FEV1/FVC ( p < 0.001) compared to placebo at the endpoint. Nano‐curcumin had a significantly increasing effect on weight and body mass index compared to the placebo group ( P ANCOVA adjusted for baseline values = 0.042). There was a meaningful improvement in systolic blood pressure in the nano‐curcumin group compared to the placebo group ( P ANCOVA adjusted for baseline values = 0.026). There was no significant difference between the two groups in terms of waist circumference, waist‐to‐hip ratio, and diastolic blood pressure ( P ANCOVA adjusted for baseline values >0.05). Nano‐curcumin supplement seems to have favorable effects on inflammation status and respiratory indices of patients with severe COPD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nutrition, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
- Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
- Department of Epidemiology and Biostatistics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
- Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran.
ORCID profiles: Rasoul Zarrin, Amir Hossein Faghfouri
Funding
- Urmia University of Medical Sciences
Cite
APA
Zare'i, M., Rabieepour, M., Ghareaghaji, R., Zarrin, R., & Faghfouri, A. H. (2024). Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial. Phytotherapy Research, 38(3), 1224-1234. https://doi.org/10.1002/ptr.8114
Vancouver
Zare'i M, Rabieepour M, Ghareaghaji R, Zarrin R, Faghfouri AH. Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial. Phytotherapy Research. 2024;38(3):1224-1234. doi:10.1002/ptr.8114
BibTeX
@article{Zarei2024,
author = {Zare'i, Mahdieh and Rabieepour, Masoumeh and Ghareaghaji, Rasoul and Zarrin, Rasoul and Faghfouri, Amir Hossein},
title = {Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial},
journal = {Phytotherapy Research},
year = {2024},
volume = {38},
number = {3},
pages = {1224--1234},
doi = {10.1002/ptr.8114}
}
EUVIMED